Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

"How Asset-Centric Biotech Structures Can Open New Avenues for Achieving Liquidity"

Summary

Speakers

Mitchell S. Bloom

Related Content

2025 HSR Thresholds Announced: $126.4 million

DEA Announces a Third Extension of COVID-19 Telehealth Flexibilities for Prescription of Controlled Medications

Business Groups File Lawsuit Challenging HSR Rule Changes

Year in Review: Top Regulatory Developments of 2024

Acuitas Sues GSK Seeking Declaratory Judgment of Invalidity and Non-Infringement of mRNA Vaccine Patents

Horizon Scanning: UK Employment Law Developments 2025

Recent Ustekinumab and Denosumab Biosimilars Deals

FDA Approves Celltrion’s STEQEYMA (ustekinumab-stba)

Goodwin Rare Disease Symposium 2025

Goodwin CLE Week 2025

IDRx To Be Acquired by GSK For $1 Billion Upfront, And Additional $150 Million in Milestones

Goodwin's Top Ranked Life Sciences Practice Enhances Intellectual Property Expertise with the Addition of Carl Morales in New York

Goodwin Advises Kelun Biotech and Harbour BioMed on License Agreement with Windward Bio for an Anti-TSLP Fully Human Antibody for Immunological Diseases for up to $970 Million Upfront and in Milestone Payments

Goodwin Advises Ouro Medicines on its $120 Million Launch and In-License for Keymed’s Novel T-Cell Engager

Goodwin Advises Absci on the Collaboration and $20 Million Strategic Investment with AMD to Accelerate the Future of AI Drug Discovery

Laura Umbrecht Gulick Recognized by Mergers & Acquisitions’ Most Influential Women in Mid-Market M&A 2025

Life Sciences